{"nctId":"NCT02512510","briefTitle":"Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2015-09"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":611,"armGroups":[{"label":"TD-4208-1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TD-4208"]},{"label":"TD-4208-2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TD-4208"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"TD-4208","otherNames":["revefenacin"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is a male or female subject 40 years of age or older\n\nExclusion Criteria:\n\n* Females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Trough FEV1 on Day 85","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115.58","spread":"18.637"},{"groupId":"OG001","value":"102.90","spread":"18.542"},{"groupId":"OG002","value":"-44.92","spread":"18.841"}]}]}]},{"type":"SECONDARY","title":"Summary of Trough FEV1 Overall Treatment Effect From Day 15 to Day 85","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":"3.14"},{"groupId":"OG001","value":"87.1","spread":"3.21"},{"groupId":"OG002","value":"-39.9","spread":"3.15"}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Baseline to Peak FEV1 After First Dose","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"218.65","spread":"10.291"},{"groupId":"OG001","value":"216.84","spread":"10.248"},{"groupId":"OG002","value":"88.22","spread":"10.092"}]}]}]},{"type":"SECONDARY","title":"Summary of Rescue Medication Use: Puffs Per Day","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"0.207"},{"groupId":"OG001","value":"2.38","spread":"0.204"},{"groupId":"OG002","value":"2.54","spread":"0.206"}]}]}]},{"type":"SECONDARY","title":"St. George's Respiratory Questionnaire (SGRQ) Proportion of Responders on Day 85","description":"A Responder is defined as someone who experienced a decrease in SGRQ score of 4 or more units","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Albuterol Rescue-free 24-hour Periods","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.79","spread":"2.800"},{"groupId":"OG001","value":"43.26","spread":"2.769"},{"groupId":"OG002","value":"37.23","spread":"2.766"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":205},"commonTop":["Chronic obstructive pulmonary disease","Cough","Headache","Dyspnoea","Upper respiratory tract infection"]}}}